专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06380183B1 Treatment of diseases involving cyst formation 有权
标题翻译：治疗涉及囊肿形成的疾病
公开(公告)号：US06380183B1
公开(公告)日：2002-04-30
申请号：US09461910
申请日：1999-12-15
申请人： George F. Schreiner , Alison Joly , Lawrence W. Stanton , R. Tyler White
发明人： George F. Schreiner , Alison Joly , Lawrence W. Stanton , R. Tyler White
IPC分类号： A61K3155
CPC分类号： A61K45/06 , A61K31/5513 , A61K38/212 , G01N33/948 , A61K2300/00
摘要： The invention concerns the use of ligands of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of diseases involving cyst formation and in particular polycystic kidney disease. The invention further concerns the treatment of hypertension accompanying polycystic kidney disease, and pharmaceutical compositions and articles of manufacture for the treatment or diagnosis of the target disease or condition.
摘要翻译：本发明涉及外周型苯二氮卓受体（PTBR）的配体在诊断和治疗涉及囊肿形成，特别是多囊肾病的疾病中的用途。本发明还涉及治疗伴随多囊肾病的高血压，以及用于治疗或诊断目标疾病或病症的药物组合物和制品。

2. 发明授权

US06342495B1 Agonists and antagonists of peripheral-type benzodiazepine receptors 有权
标题翻译：外周型苯二氮类受体的激动剂和拮抗剂
公开(公告)号：US06342495B1
公开(公告)日：2002-01-29
申请号：US09461780
申请日：1999-12-15
申请人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
发明人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
IPC分类号： A61K3155
CPC分类号： C12Q1/6883 , C12Q2600/158
摘要： The invention concerns the use of agonists and antagonists of peripheral-type benzodiazcpine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.
摘要翻译：本发明涉及外周型苯并二氮对受体（PTBR）的激动剂和拮抗剂在心脏肥大和其它循环状况的诊断和治疗中的应用。本发明具体涉及使用PTBR拮抗剂来预防或治疗失代偿性心脏肥大，最终导致心力衰竭。本发明还涉及PTBR激动剂在管理呼吸增加的血流量或心输出量的情况下的应用，包括对心脏的损伤或功能损害，对体育运动的增加的需求，或心脏收缩功能障碍的获得或遗传倾向。还包括用于治疗这些病症的药物组合物和鉴定PTBR激动剂和拮抗剂的筛选方法。

3. 发明授权

US06709855B1 Methods for detection and use of differentially expressed genes in disease states 有权
标题翻译：在疾病状态下检测和使用差异表达基因的方法
公开(公告)号：US06709855B1
公开(公告)日：2004-03-23
申请号：US09461912
申请日：1999-12-15
申请人： Lawrence W. Stanton , R. Tyler White , Deborah L. Damm , John A. Lewicki , Alison Joly , George F. Schreiner
发明人： Lawrence W. Stanton , R. Tyler White , Deborah L. Damm , John A. Lewicki , Alison Joly , George F. Schreiner
IPC分类号： C12M134
CPC分类号： C12Q1/6876 , C12Q1/6837 , C12Q2600/158
摘要： The present invention relates to methods and compositions for the detection, diagnosis, prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and related disorders. The present invention also relates to compositions and methods useful in the diagnosis, prevention and therapeutic treatment of a disease, specifically cardiac, kidney or inflammatory disease. Specifically, methods and compositions are provided for the diagnostic evaluation and prognosis of conditions involving a disease, specifically cardiac, kidney or inflammatory disease, for the identification of subjects exhibiting a predisposition to such conditions, for modulating the effect of these differentially expressed genes, for monitoring patients undergoing clinical evaluation for the prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and its disorders, and for monitoring the efficacy of compounds used in clinical trials.
摘要翻译：本发明涉及用于检测，诊断，预防和治疗疾病，特别是心脏，肾脏或炎症性疾病以及相关疾病的方法和组合物。本发明还涉及用于诊断，预防和治疗疾病，特别是心脏，肾脏或炎性疾病的组合物和方法。具体地，提供方法和组合物用于诊断评估和预后涉及疾病，特别是心脏，肾脏或炎性疾病的疾病，用于鉴定表现出对这些病症倾向的受试者，用于调节这些差异表达基因的作用，用于监测接受临床评估的患者，用于预防和治疗疾病，特别是心脏，肾脏或炎症疾病及其疾病，并监测临床试验中使用的化合物的功效。

4. 发明授权

US06686354B2 Agonists and antagonists of peripheral-type benzodiazepine receptors 有权
标题翻译：外周型苯二氮类受体的激动剂和拮抗剂
公开(公告)号：US06686354B2
公开(公告)日：2004-02-03
申请号：US10033189
申请日：2001-12-27
申请人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
发明人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
IPC分类号： A61K3155
CPC分类号： C12Q1/6883 , C12Q2600/158
摘要： The invention concerns the use of agonists and antagonists of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.
摘要翻译：本发明涉及外周型苯二氮卓受体（PTBR）的激动剂和拮抗剂在心脏肥大和其他循环状况的诊断和治疗中的应用。本发明具体涉及使用PTBR拮抗剂来预防或治疗失代偿性心脏肥大，最终导致心力衰竭。本发明还涉及PTBR激动剂在管理呼吸增加的血流量或心输出量的情况下的应用，包括对心脏的损伤或功能损害，对体育运动的增加的需求，或心脏收缩功能障碍的获得或遗传倾向。还包括用于治疗这些病症的药物组合物和鉴定PTBR激动剂和拮抗剂的筛选方法。

5. 发明授权

US06800455B2 Secreted factors 有权
标题翻译：分散因素
公开(公告)号：US06800455B2
公开(公告)日：2004-10-05
申请号：US09809545
申请日：2001-03-14
申请人： Lawrence W. Stanton , R. Tyler White
发明人： Lawrence W. Stanton , R. Tyler White
IPC分类号： C12P2106
CPC分类号： C07K14/47
摘要： The invention concerns new secreted factors encoded by clones P00184_D11 (SEQ ID NO:1), P00185_D11 (SEQ ID NO:3), P00188_D12 (SEQ ID NO:5), P00188_E01 (SEQ ID NO:7), P00194_G01 (SEQ ID NO:9), P00194_G05 (SEQ ID NO:11), P00194_H10 (SEQ ID NO:13), P00199_D08 (SEQ ID NO:15), P00203_D04 (SEQ ID NO:17), P00203_E06 (SEQ ID NO:19), P00209_F06 (SEQ ID NO:21), P00219_D02 (SEQ ID NO:23), P00219_F06 (SEQ ID NO:25), P00220_H05 (SEQ ID NO:27), P00222_G03 (SEQ ID NO:29), P00225_C01 (SEQ ID NO:32), P00227_D11 (SEQ ID NO:34), P00228_F03 (SEQ ID NO:36), P00233_H08 (SEQ ID NO:38), P00235_G08 (SEQ ID NO:40), P00239_C11 (SEQ ID NO:42), P00240_E05 (SEQ ID NO:45), P00247_A04 (SEQ ID NO:50), P00248_B04 (SEQ ID NO:52), P00249_F09 (SEQ ID NO:54), P00258_A10 (SEQ ID NO:56), P00262_C10 (SEQ ID NO:58), P00269_H08 (SEQ ID NO:62), P00628_H02 (SEQ ID NO:66), P00629_C08 (SEQ ID NO:68), P00641_G11 (SEQ ID NO:71), P00648_E12 (SEQ ID NO:73), P00697_C03 (SEQ ID NO:75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.
摘要翻译：本发明涉及由克隆P00184_D11（SEQ ID NO：1），P00185_D11（SEQ ID NO：3），P00188_D12（SEQ ID NO：5），P00188_E01（SEQ ID NO：7），P00194_G01（SEQ ID NO： P00194_G05（SEQ ID NO：11），P00194_H10（SEQ ID NO：13），P00199_D08（SEQ ID NO：15），P00203_D04（SEQ ID NO：17），P00203_E06（SEQ ID NO：19），P00209_F06 （SEQ ID NO：21），P00219_D02（SEQ ID NO：23），P00219_F06（SEQ ID NO：25），P00220_H05（SEQ ID NO：27），P00222_G03（SEQ ID NO：29），P00225_C01 P00227_D11（SEQ ID NO：34），P00228_F03（SEQ ID NO：36），P00233_H08（SEQ ID NO：38），P00235_G08（SEQ ID NO：40），P00239_C11（SEQ ID NO：42），P00240_E05 P00248_A04（SEQ ID NO：50），P00248_B04（SEQ ID NO：52），P00249_F09（SEQ ID NO：54），P00258_A10（SEQ ID NO：56），P00262_C10（SEQ ID NO：），P00269_H08（SEQ ID NO：62），P00628_H02（SEQ ID NO：66），P00629_C08（SEQ ID NO：68），P00641_G11（SEQ ID NO：71），P00648_E12（SEQ ID NO：73），P00697_C03 SEQ ID NO：75）和其他哺乳动物同系物及其变体因子，以及编码它们的多核苷酸。本发明还涉及用于产生这些因素及其在诊断和治疗各种心脏，肾脏或炎症疾病中的用途的方法和手段。

6. 发明授权

US07202344B2 Secreted factors 有权
标题翻译：分散因素
公开(公告)号：US07202344B2
公开(公告)日：2007-04-10
申请号：US10959440
申请日：2004-10-05
申请人： Lawrence W. Stanton , R. Tyler White
发明人： Lawrence W. Stanton , R. Tyler White
IPC分类号： C07K16/00 , C07K16/18 , G01N33/53 , G01N33/563
CPC分类号： C07K14/47
摘要： The invention concerns new secreted factors encoded by clones P00184_D11 (SEQ ID NO: 1), P00185_D11 (SEQ ID NO: 3), P00188_D12 (SEQ ID NO: 5), P00188_E01 (SEQ ID NO: 7), P00194_G01 (SEQ ID NO: 9), P00194_G05 (SEQ ID NO: 11), P00194_H10 (SEQ ID NO: 13), P00199_D08 (SEQ ID NO: 15), P00203_D04 (SEQ ID NO: 17), P00203_E06 (SEQ ID NO: 19), P00209_F06 (SEQ ID NO: 21), P00219_D02 (SEQ ID NO: 23), P00219_F06 (SEQ ID NO: 25), P00220_H05 (SEQ ID NO: 27), P00222_G03 (SEQ ID NO: 29), P00225_C01 (SEQ ID NO: 32), P00227_D11 (SEQ ID NO: 34), P00228_F03 (SEQ ID NO: 36), P00233_H08 (SEQ ID NO: 38), P00235_G08 (SEQ ID NO: 40), P00239_C11 (SEQ ID NO: 42), P00240_E05 (SEQ ID NO: 45), P00247_A04 (SEQ ID NO: 50), P00248_B04 (SEQ ID NO: 52), P00249_F09 (SEQ ID NO: 54), P00258_A10 (SEQ ID NO: 56), P00262_C10 (SEQ ID NO: 58), P00269_H08 (SEQ ID NO: 62), P00628_H02 (SEQ ID NO: 66), P00629_C08 (SEQ ID NO: 68), P00641_G11 (SEQ ID NO: 71), P00648_E12 (SEQ ID NO: 73), P00697_C03 (SEQ ID NO: 75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.
摘要翻译：本发明涉及由克隆P00184_D11（SEQ ID NO：1），P00185_D11（SEQ ID NO：3），P00188_D12（SEQ ID NO：5），P00188_E01（SEQ ID NO：7），P00194_G01（SEQ ID NO： P00194_G05（SEQ ID NO：11），P00194_H10（SEQ ID NO：13），P00199_D08（SEQ ID NO：15），P00203_D04（SEQ ID NO：17），P00203_E06（SEQ ID NO：19），P00209_F06 （SEQ ID NO：21），P00219_D02（SEQ ID NO：23），P00219_F06（SEQ ID NO：25），P00220_H05（SEQ ID NO：27），P00222_G03（SEQ ID NO：29），P00225_C01 P00227_D11（SEQ ID NO：34），P00228_F03（SEQ ID NO：36），P00233_H08（SEQ ID NO：38），P00235_G08（SEQ ID NO：40），P00239_C11（SEQ ID NO：42），P00240_E05 P00248_A04（SEQ ID NO：50），P00248_B04（SEQ ID NO：52），P00249_F09（SEQ ID NO：54），P00258_A10（SEQ ID NO：56），P00262_C10（SEQ ID NO：），P00269_H08（SEQ ID NO：62），P00628_H02（SEQ ID NO：66），P00629_C08（SEQ ID NO：68），P00641_G11（SEQ ID NO：71），P00648_E12（SEQ ID NO：73），P00697_C03 ID NO：75）和其他哺乳动物这些因子的同系物和变体，以及编码它们的多核苷酸。本发明还涉及用于产生这些因素及其在诊断和治疗各种心脏，肾脏或炎症疾病中的用途的方法和手段。

7. 发明申请

US20090304642A1 METHODS OF SPECIFYING MESODERMAL, ENDODERMAL AND MESOENDODERMAL CELL FATES 失效
标题翻译：指定MERMODMAL，ENDODERMAL和MESOENDODERMELL细胞FATES的方法
公开(公告)号：US20090304642A1
公开(公告)日：2009-12-10
申请号：US12091210
申请日：2006-10-25
申请人： Manjiri Bakre , Lawrence W. Stanton
发明人： Manjiri Bakre , Lawrence W. Stanton
IPC分类号： A61K35/12 , C12N5/08 , A61P43/00
CPC分类号： A61K38/1709 , C07K14/475 , C12N5/0606 , C12N2501/415 , C12N2506/02
摘要： We disclose a method for producing a mesodermal or a endodermal cell from a pluripotent stem cell, the method comprising activating a Wnt signalling pathway in the pluripotent stem cell. In some embodiments, the pluripotent stem cell is in a substantially 2 dimensional configuration, such as a monolayer, for at least a portion of the time when the Wnt signalling pathway is activated.
摘要翻译：我们公开了从多能干细胞产生中胚层或内胚层细胞的方法，该方法包括激活多能干细胞中的Wnt信号通路。在一些实施方案中，在Wnt信号通路被激活的时间的至少一部分时间内，多能干细胞处于基本上二维构型，例如单层。

8. 发明申请

US20090263835A1 Genes that are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells 审中-公开
标题翻译：在人类胚胎干细胞分化过程中上调或下调的基因
公开(公告)号：US20090263835A1
公开(公告)日：2009-10-22
申请号：US12487869
申请日：2009-06-19
申请人： Lawrence W. Stanton , Ralph Brandenberger , Joseph D. Gold , John M. Irving , Ramkumar Mandalam , Michael Mok , Dawne Shelton
发明人： Lawrence W. Stanton , Ralph Brandenberger , Joseph D. Gold , John M. Irving , Ramkumar Mandalam , Michael Mok , Dawne Shelton
IPC分类号： G01N33/53
CPC分类号： C12Q1/6876 , C12Q1/68 , C12Q1/6886 , C12Q2600/158
摘要： Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy.
摘要翻译：在分化期间上调或下调的基因提供了表征和操纵早期多能干细胞的重要作用。已经从未分化的人类胚胎干细胞和三种类型的分化后代中扩增和测序了超过35,000个独特的转录物。组装的转录物的统计分析确定了在分化进行时改变表达水平的基因。表达谱提供了用于鉴定用于维持未分化表型的特定培养组分的标记系统。基因产物也可用于促进分化; 评估其他相对未分化的细胞（如癌细胞）; 控制基因表达; 或分离具有所需特征的细胞。特定基因的操作可用于预防或集中分化过程，途径是产生适合人类治疗的专门的均质细胞群。

9. 发明授权

US06322976B1 Compositions and methods of disease diagnosis and therapy 失效
标题翻译：疾病诊断和治疗的组成和方法
公开(公告)号：US06322976B1
公开(公告)日：2001-11-27
申请号：US09270542
申请日：1999-03-17
申请人： Timothy J. Aitman , James Scott , Lawrence W. Stanton
发明人： Timothy J. Aitman , James Scott , Lawrence W. Stanton
IPC分类号： C12Q168
CPC分类号： C07K14/70596 , A61K38/00 , Y02A50/411
摘要： The invention pertains to isolated nucleic acid molecules containing sequences specified herein, to mutant CD36 genes and their encoded gene products, to methods of screening blood or a blood product by detecting a CD36 gene mutation, methods of administering blood or a blood product based on the presence or absence of a CD36 gene mutation, to methods of matching a biological sample donor with a recipient based on detection of a mutation in the CD36 gene, methods of determining the resistance of a patient to infection by a parasite by detecting a CD36 gene mutation, methods of diagnosing a disease associated with a defect in insulin action, glucose metabolism, fatty acid metabolism, and/or catecholamine action by detecting a mutation in the CD36 gene, and methods of disease treatment by altering the mutation(s).
摘要翻译：本发明涉及含有本文规定的序列的分离的核酸分子，突变型CD36基因及其编码的基因产物，通过检测CD36基因突变筛选血液或血液制品的方法，基于所述方法给予血液或血液制品 CD36基因突变的存在或不存在，基于CD36基因突变检测将生物样品供体与受体相匹配的方法，通过检测CD36基因突变来确定患者对寄生虫感染的抗性的方法通过检测CD36基因中的突变来诊断与胰岛素作用缺陷相关的疾病，葡萄糖代谢，脂肪酸代谢和/或儿茶酚胺作用的方法，以及通过改变突变的疾病治疗方法。

10. 发明授权

US08907055B2 Mutant sox proteins and methods of inducing pluripotency 有权
标题翻译：突变型sox蛋白和诱导多能性的方法
公开(公告)号：US08907055B2
公开(公告)日：2014-12-09
申请号：US13505369
申请日：2010-11-04
申请人： Prasanna R. Kolatkar , Irene Aksoy , Ralf Jauch , Lawrence W. Stanton
发明人： Prasanna R. Kolatkar , Irene Aksoy , Ralf Jauch , Lawrence W. Stanton
IPC分类号： A61K38/00 , C07H21/04 , C12N5/00
CPC分类号： C07K14/4702 , C12N15/62
摘要： There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.
摘要翻译：目前提供了在部分分化或完全分化的细胞中获得或增加诱导多能性的能力的突变Sox2，Sox7和Sox17蛋白。 Sox7和Sox17被突变以类似于部分Sox2，或者Sox2被突变以类似于部分Sox7或Sox17。在一方面，Sox7或Sox17的Oct4接触界面被突变。另一方面，Sox2的高迁移率组（HMG）融合到Sox7或Sox17的C末端激活结构域。还提供了使用突变Sox2，Sox7或Sox17蛋白诱导多能性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式